Women and peripheral arterial disease

Women's Health

Volumn 5, Issue 6, 2009, Pages 669-683

  Vavra, Ashley K ^a   Kibbe, Melina R ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Gender; Peripheral arterial disease; Women

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE BESYLATE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CARNITINE; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NAFTIDROFURYL; SIMVASTATIN;

ABOVE KNEE AMPUTATION; ANKLE BRACHIAL INDEX; ANTICOAGULATION; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; GANGRENE; GRAFT PATENCY; HEALTH CARE ACCESS; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; ISCHEMIA; LIMB AMPUTATION; LIMB ISCHEMIA; LIMB SALVAGE; MENOPAUSAL SYNDROME; MORBIDITY; MORTALITY; NECROSIS; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; STROKE; TRANSIENT ISCHEMIC ATTACK; VASODILATATION; VENOUS THROMBOEMBOLISM; WALKING DIFFICULTY; WOMEN'S HEALTH; WOUND COMPLICATION;

AGE FACTORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR AGENTS; COMORBIDITY; ESTROGEN REPLACEMENT THERAPY; EXERCISE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PERIPHERAL VASCULAR DISEASES; POSTMENOPAUSE; PREVALENCE; RISK FACTORS; SEX FACTORS; SMOKING; WOMEN'S HEALTH;

EID: 70649101393     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.60     Document Type: Review

References (89)

1. Criqui MH: Peripheral arterial disease - epidemiological aspects. Vasc. Med. 6(Suppl. 3), 3-7 (2001).
2. Aboyans V, Criqui MH, McClelland RL et al.: Intrinsic contribution of gender and ethnicity to normal ankle-brachial index values: the Multi-Ethnic Study of Atherosclerosis (MESA). J. Vasc. Surg. 45(2), 319-327 (2007).
3. Hirsch AT, Haskal ZJ, Hertzer NR et al.: ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113(11), E463-E654 (2006). •• American College of Cardiology and American Heart Association joint guidelines, including the most recent recommendations for the diagnosis and treatment of peripheral arterial disease (PAD).
4. Weitz JI, Byrne J, Clagett GP et al.: Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94(11), 3026-3049 (1996).
5. Dormandy J, Belcher G, Broos P et al.: Prospective study of 713 below-knee amputations for ischaemia and the effect of a prostacyclin analogue on healing. Hawaii Study Group. Br. J. Surg. 81(1), 33-37 (1994).
6. Hirsch AT, Criqui MH, Treat-Jacobson D et al.: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286(11), 1317-1324 (2001).
7. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J. Vasc. Surg. 45(Suppl.) S5-S67 (2007).
8. Sigvant B, Wiberg-Hedman K, Bergqvist D et al.: A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J. Vasc. Surg. 45(6), 1185-1191 (2007). • large population-based study.
9. Diehm C, Schuster A, Allenberg JR et al.: High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 172(1), 95-105 (2004). • large population-based study.
10. Moussa ID, Jaff MR, Mehran R et al.: Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the Peripheral Arterial Disease in Interventional Patients Study. Catheter. Cardiovasc. Interv. 73(6), 719-724 (2009).
11. Collins TC, Suarez-Almazor M, Bush RL, Petersen NJ: Gender and peripheral arterial disease. J. Am. Board Fam. Med. 19(2), 132-140 (2006).
12. Kroger K, Stang A, Kondratieva J et al.: Prevalence of peripheral arterial disease - results of the Heinz Nixdorf recall study. Eur. J. Epidemiol. 21(4), 279-285 (2006). • large population-based study.
13. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP: Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J. Am. Geriatr. Soc. 55(4), 583-589 (2007). • Large population-based study.
14. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D: The prevalence of peripheral arterial disease in a defined population. Circulation 71(3), 510-515 (1985).
15. Selvin E, Erlinger TP: Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110(6), 738-743 (2004).
16. He Y, Jiang Y, Wang J, Fan L, Li X, Hu FB: Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. J. Vasc. Surg. 44(2), 333-338 (2006).
17. Deneuville M, Pierrot JM, N'guyen R: Particularities of peripheral arterial disease managed in vascular surgery in the French West Indies. Arch. Cardiovasc. Dis. 101(1), 23-29 (2008).
18. Vogt MT, Cauley JA, Kuller LH, Hulley SB: Prevalence and correlates of lower extremity arterial disease in elderly women. Am. J. Epidemiol. 137(5), 559-568 (1993).
19. McDermott MM, Greenland P, Liu K et al.: Sex differences in peripheral arterial disease: leg symptoms and physical functioning. J. Am. Geriatr. Soc. 51(2), 222-228 (2003).
20. Vogt MT, Cauley JA, Kuller LH, Nevitt MC: Functional status and mobility among elderly women with lower extremity arterial disease: the Study of Osteoporotic Fractures. J. Am. Geriatr. Soc. 42(9), 923-929 (1994).
21. Feinglass J, McDermott MM, Foroohar M, Pearce WH: Gender differences in interventional management of peripheral vascular disease: evidence from a blood flow laboratory population. Ann. Vasc. Surg. 8(4), 343-349 (1994).
22. Brevetti G, Bucur R, Balbarini A et al.: Women and peripheral arterial disease: same disease, different issues. J. Cardiovasc. Med. (Hagerstown.) 9(4), 382-388 (2008).
23. Kullo IJ, Bailey KR, Kardia SL, Mosley TH Jr, Boerwinkle E, Turner ST: Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc. Med. 8(4), 237-242 (2003).
24. Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM: The prevalence of peripheral arterial disease in a racially diverse population. Arch. Intern. Med. 163(12), 1469-1474 (2003).
25. Newman AB, Siscovick DS, Manolio TA et al.: Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 88(3), 837-845 (1993).
26. Gerhard M, Baum P, Raby KE: Peripheral arterial-vascular disease in women: prevalence, prognosis, and treatment. Cardiology 86(4), 349-355 (1995).
27. Zheng ZJ, Rosamond WD, Chambless LE et al.: Lower extremity arterial disease assessed by ankle-brachial index in a middle-aged population of African-Americans and whites: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Prev. Med. 29(5 Suppl. 1), 42-49 (2005).
28. McDermott MM, Fried L, Simonsick E, Ling S, Guralnik JM: Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the women's health and aging study. Circulation 101(9), 1007-1012 (2000).
29. Willigendael EM, Teijink JA, Bartelink ML et al.: Influence of smoking on incidence and prevalence of peripheral arterial disease. J. Vasc. Surg. 40(6), 1158-1165 (2004).
30. Jensen SA, Vatten LJ, Myhre HO: The prevalence of chronic critical lower limb ischaemia in a population of 20,000 subjects 40-69 years of age. Eur. J. Vasc. Endovasc. Surg. 32(1), 60-65 (2006).
31. Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GD, Fowkes FG: Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur. Heart J. 20(5), 344-353 (1999).
32. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF: Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 96(1), 44-49 (1997).
33. Cigarette smoking among adults - United States, 2006. Morb. Mortal. Wkly Rep. 56(44), 1157-1161 (2007).
34. Tseng CH: Sex difference in the distribution of atherosclerotic risk factors and their association with peripheral arterial disease in Taiwanese Type 2 diabetic patients. Circ. J. 71(7), 1131-1136 (2007).
35. Gardner AW: Sex differences in claudication pain in subjects with peripheral arterial disease. Med. Sci. Sports Exerc. 34(11), 1695-1698 (2002).
36. Kannel WB, McGee DL: Update on some epidemiologic features of intermittent claudication: the Framingham Study. J. Am. Geriatr. Soc. 33(1), 13-18 (1985).
37. McDermott MM, Guralnik JM, Ferrucci L et al.: Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation 117(19), 2484-2491 (2008).
38. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97(5), 425-428 (1998).
39. Vidula H, Tian L, Liu K et al.: Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann. Intern. Med. 148(2), 85-93 (2008).
40. Lakoski SG, Cushman M, Criqui M et al.: Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am. Heart J. 152(3), 593-598 (2006).
41. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Wahlberg E: Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. Eur. J. Cardiovasc. Prev. Rehabil. 16(1), 39-46 (2009).
42. Monreal M, Alvarez L, Vilaseca B et al.: Clinical outcome in patients with peripheral artery disease. Results from a prospective registry (FRENA). Eur. J. Intern. Med. 19(3), 192-197 (2008).
43. Froehlich JB, Mukherjee D, Avezum A et al.: Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Am. Heart J. 151(5), 1123-1128 (2006).
44. Mazhari R, Hsia J: Prevalence, clinical significance, and management of peripheral arterial disease in women: is there a role for postmenopausal hormone therapy? Vasc. Health Risk Manag. 1(2), 111-117 (2005).
45. McBride SM, Flynn FW, Ren J: Cardiovascular alteration and treatment of hypertension: do men and women differ? Endocrine 28(2), 199-207 (2005).
46. Westendorp IC, in't Veld BA, Grobbee DE et al.: Hormone replacement therapy and peripheral arterial disease: the Rotterdam study. Arch. Intern. Med. 160(16), 2498-2502 (2000).
47. Hulley S, Grady D, Bush T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 280(7), 605-613 (1998). •• Landmark randomized, prospective, controlled trial that examined the effect of combined estrogen and progestin hormone-replacement therapy in women with cardiovascular disease.
48. Rossouw JE, Anderson GL, Prentice RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
49. Grady D, Herrington D, Bittner V et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA 288(1), 49-57 (2002). • Long-term follow-up data for the Heart and Estrogen/Progestin Replacement Study.
50. Hsia J, Aragaki A, Bloch M, LaCroix AZ, Wallace R: Predictors of angina pectoris versus myocardial infarction from the Women's Health Initiative Observational Study. Am. J. Cardiol. 93(6), 673-678 (2004). •• Landmark randomized, prospective, controlled trial that examined the effect of combined estrogen and progestin hormone-replacement therapy on cardiovascular risk in women.
51. Hsia J, Simon JA, Lin F et al.: Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation 102(18), 2228-2232 (2000).
52. Hsia J, Criqui MH, Herrington DM et al.: Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. Am. Heart J. 152(1), 170-176 (2006). •• Landmark randomized, prospective, controlled trial that examined the effect of estrogen-alone hormone-replacement therapy on cardiovascular risk in women with a history of hysterectomy.
53. Timaran CH, Stevens SL, Freeman MB, Goldman MH: Infrainguinal arterial reconstructions in patients with aortoiliac occlusive disease: the influence of iliac stenting. J. Vasc. Surg. 34(6), 971-978 (2001).
54. Timaran CH, Stevens SL, Grandas OH, Piercy KT, Freeman MB, Goldman MH: Influence of hormone replacement therapy on graft patency after femoropopliteal bypass grafting. J. Vasc. Surg. 32(3), 506-516 (2000).
55. Vouyouka AG, Kent KC: Arterial vascular disease in women. J. Vasc. Surg. 46(6), 1295-1302 (2007).
56. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE: Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler. Thromb. Vasc. Biol. 18(2), 185-192 (1998).
57. Cheanvechai V, Harthun NL, Graham LM, Freischlag JA, Gahtan V: Incidence of peripheral vascular disease in women: is it different from that in men? J. Thorac. Cardiovasc. Surg. 127(2), 314-317 (2004).
58. Feinglass J, Kaushik S, Handel D, Kosifas A, Martin GJ, Pearce WH: Peripheral bypass surgery and amputation: northern Illinois demographics, 1993 to 1997. Arch. Surg. 135(1), 75-80 (2000).
59. Eslami MH, Zayaruzny M, Fitzgerald GA: The adverse effects of race, insurance status, and low income on the rate of amputation in patients presenting with lower extremity ischemia. J. Vasc. Surg. 45(1), 55-59 (2007).
60. Bloemenkamp DG, Mali WP, Tanis BC et al.: Functional health and well-being of relatively young women with peripheral arterial disease is decreased but stable after diagnosis. J. Vasc. Surg. 38(1), 104-110 (2003).
61. Arseven A, Guralnik JM, O'Brien KE, Liu K, Chan C, McDermott MM: Does lower-extremity arterial disease predict future falling among older men and women? Angiology 58(6), 725-733 (2007).
62. Oka RK, Szuba A, Giacomini JC, Cooke JP: Gender differences in perception of PAD: a pilot study. Vasc. Med. 8(2), 89-94 (2003).
63. Breek JC, Hamming JF, De VJ, van Berge Henegouwen DP, van Heck GL: The impact of walking impairment, cardiovascular risk factors, and comorbidity on quality of life in patients with intermittent claudication. J. Vasc. Surg. 36(1), 94-99 (2002).
64. McDermott MM, Ades P, Guralnik JM et al.: Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 301(2), 165-174 (2009).
65. Stein R, Hriljac I, Halperin JL, Gustavson SM, Teodorescu V, Olin JW: Limitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial disease. Vasc. Med. 11(1), 29-33 (2006).
66. Ouriel K, McDonnell AE, Metz CE, Zarins CK: Critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery 91(6), 686-693 (1982).
67. Bild DE, Bluemke DA, Burke GL et al.: Multi-ethnic study of atherosclerosis: objectives and design. Am. J. Epidemiol. 156(9), 871-881 (2002).
68. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ: Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int. J. Epidemiol. 20(2), 384-392 (1991).
69. Hiatt WR, Hoag S, Hamman RF: Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 91(5), 1472-1479 (1995).
70. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC: Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation. 109(9), 1089-1094 (2004).
71. Morillas P, Cordero A, Bertomeu V et al.: Prognostic value of low ankle-brachial index in patients with hypertension and acute coronary syndromes. J. Hypertens. 27(2), 341-347 (2009).
72. McDermott MM, Ferrucci L, Simonsick EM et al.: The ankle brachial index and change in lower extremity functioning over time: the Women's Health and Aging Study. J. Am. Geriatr. Soc. 50(2), 238-246 (2002).
73. Lonn E, Roccaforte R, Yi Q et al.: Effect of long-term therapy with ramipril in high-risk women. J. Am. Coll. Cardiol. 40(4), 693-702 (2002).
74. Herrington DM, Vittinghoff E, Lin F et al.: Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 105(25), 2962-2967 (2002).
75. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348(9038), 1329-1339 (1996).
76. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR: Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-ana lysis of randomized trials. JAMA 301(18), 1909-1919 (2009).
77. Zeymer U, Parhofer KG, Pittrow D et al.: Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clin. Res. Cardiol. 98(4), 249-256 (2009).
78. Watson L, Ellis B, Leng GC: Exercise for intermittent claudication. Cochrane Database Syst. Rev. 4, CD000990 (2008).
79. Mohler ER, III, Hiatt WR, Creager MA: Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108(12), 1481-1486 (2003).
80. Mondillo S, Ballo P, Barbati R et al.: Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am. J. Med. 114(5), 359-364 (2003).
81. Regensteiner JG, Ware JE Jr, McCarthy WJ et al.: Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-ana lysis of six randomized controlled trials. J. Am. Geriatr. Soc. 50(12), 1939-1946 (2002).
82. Roddy SP, Darling RC III, Maharaj D et al.: Gender-related differences in outcome: an ana lysis of 5880 infrainguinal arterial reconstructions. J. Vasc. Surg. 37(2), 399-402 (2003).
83. Eugster T, Gurke L, Obeid T, Stierli P: Infrainguinal arterial reconstruction: female gender as risk factor for outcome. Eur. J. Vasc. Endovasc. Surg. 24(3), 245-248 (2002).
84. AhChong AK, Chiu KM, Wong M, Yip AW: The influence of gender difference on the outcomes of infrainguinal bypass for critical limb ischaemia in Chinese patients. Eur. J. Vasc. Endovasc. Surg. 23(2), 134-139 (2002).
85. Ascer E, White SA, Veith FJ, Morin L, Freeman K, Gupta SK: Outflow resistance measurement during infrainguinal arterial reconstructions: a reliable predictor of limb salvage. Am. J. Surg. 154(2), 185-188 (1987).
86. Belkin M, Conte MS, Donaldson MC, Mannick JA, Whittemore AD: The impact of gender on the results of arterial bypass with in situ greater saphenous vein. Am. J. Surg. 170(2), 97-102 (1995).
87. Nguyen LL, Brahmanandam S, Bandyk DF et al.: Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an ana lysis of 1404 operations for critical limb ischemia. J. Vasc. Surg. 46(6), 1191-1197 (2007).
88. Magnant JG, Cronenwett JL, Walsh DB, Schneider JR, Besso SR, Zwolak RM: Surgical treatment of infrainguinal arterial occlusive disease in women. J. Vasc. Surg. 17(1), 67-76 (1993).
89. Mays BW, Towne JB, Fitzpatrick CM et al.: Women have increased risk of perioperative myocardial infarction and higher long-term mortality rates after lower extremity arterial bypass grafting. J. Vasc. Surg. 29(5), 807-812 (1999).